Nomura update “We believe the EMA decision is due in the short-term”
1H13 – awaiting EMA registration decision
We continue to believe that there is a very high possibility of CUV getting afamelanotide to the market. This points to cashflow from sales, and sooner than for most other biotechnology companies
Download the PDF to access the full report.